These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 18626572)
1. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Tamaskar I; Mekhail T; Dreicer R; Olencki T; Roman S; Elson P; Bukowski RM Invest New Drugs; 2008 Dec; 26(6):553-9. PubMed ID: 18626572 [TBL] [Abstract][Full Text] [Related]
2. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569 [TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724 [TBL] [Abstract][Full Text] [Related]
5. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270 [TBL] [Abstract][Full Text] [Related]
6. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770 [TBL] [Abstract][Full Text] [Related]
7. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer]. Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636 [TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of temozolomide using an extended continuous oral schedule. Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665 [TBL] [Abstract][Full Text] [Related]
10. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Kim KB; Hwu WJ; Papadopoulos NE; Bedikian AY; Camacho LH; Ng C; Hernandez IM; Frost AM; Jack MA; Hwu P Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462 [TBL] [Abstract][Full Text] [Related]
12. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145 [TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660 [TBL] [Abstract][Full Text] [Related]
16. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335 [TBL] [Abstract][Full Text] [Related]
17. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors. Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606 [TBL] [Abstract][Full Text] [Related]
18. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648 [TBL] [Abstract][Full Text] [Related]
19. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Goel S; Desai K; Macapinlac M; Wadler S; Goldberg G; Fields A; Einstein M; Volterra F; Wong B; Martin R; Mani S Invest New Drugs; 2006 Mar; 24(2):125-34. PubMed ID: 16683205 [TBL] [Abstract][Full Text] [Related]
20. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Agarwala SS; Kirkwood JM Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]